医学
表皮生长因子受体
肺癌
埃罗替尼
酪氨酸激酶
奥西默替尼
酪氨酸激酶抑制剂
肿瘤科
人口
癌症研究
表皮生长因子受体抑制剂
内科学
癌症
受体
环境卫生
作者
Yang-Si Li,Guang-Ling Jie,Yi-Long Wu
标识
DOI:10.1177/17588359231193726
摘要
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line option for non-small-cell lung cancer (NSCLC) harboring active EGFR mutations. The overall survival of patients with advanced NSCLC has improved dramatically with the development of comprehensive genetic profiles and targeted therapies. However, resistance inevitably occurs, leading to disease progression after approximately 10–18 months of EGFR-TKI treatment. Platinum-based chemotherapy is the standard treatment for patients who have experienced disease progression while undergoing EGFR-TKI treatment, but its efficacy is limited. The management of extensively pretreated patients with EGFR-mutant NSCLC is becoming increasingly concerning. New agents have shown encouraging efficacy in clinical trials for this patient population, including fourth-generation EGFR-TKIs, EGFR-TKIs combined with counterpart targeted drugs, and novel agents such as antibody–drug conjugates. We review current efforts to manage extensively pretreated patients with EGFR-mutant NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI